Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05633602 |
|
Recruitment Status :
Recruiting
First Posted : December 1, 2022
Last Update Posted : February 8, 2024
|
Sponsor:
SWOG Cancer Research Network
Collaborators:
National Cancer Institute (NCI)
Eli Lilly and Company
Merck Sharp & Dohme LLC
Information provided by (Responsible Party):
SWOG Cancer Research Network
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 15, 2025 |
| Estimated Study Completion Date : | March 15, 2028 |